Category: Johnson & Johnson
-
FTC urges Fourth Circuit to reverse summary judgment for Johnson & Johnson in Stelara antitrust suit: âspecific intent not required to prove monopolizationâ
The U.S. Federal Trade Commission has told the Fourth Circuit that a Virginia court wrongly required proof of specific intent before CareFirstâs Stelara biosimilar-patent monopoly claims against Johnson & Johnson could proceed.
-
Jury accepts “reverse doctrine of equivalents” defense in blood pump patent case involving Johnson & Johnson unit
Abiomed and Maquet have been engaged in a long-running battle over blood pump technology.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technologyÂ
Bayerâs Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.